Treatment For Newly Diagnosed Myeloma

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Debate: What is the best induction therapy for transplant-eligible patients? Sequential therapy. 1 Tomer M. Mark Department of Medicine, Division of Hematology.
Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Maintenance Therapy in Multiple Myeloma
Facon T et al. Proc ASH 2013;Abstract 2.
Should Alkylators be used Upfront in Transplant-Ineligible Patients? NO!! Lymphoma-Myeloma October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Update on transplant-ineligible patients: Which regimens are best?
Ravi Vij MD Associate Professor Section of BMT and Leukemia
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.
Roman Hájek on behalf of CMG March 27, 2010 Roman Hájek on behalf of CMG March 27, 2010 „Treatment standards, in Czech Republic”.
Induction Therapies in Transplant Eligible Patients Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College.
Should Complete Remission be the goal for everyone? NO! Lymphoma Myeloma 2014 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
Palumbo A et al. Proc ASH 2012;Abstract 446.
Optimal Use of Newly Approved Agents – Carfilzomib and Pomalidomide Lymphoma-Myeloma Symposium October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Strategies for front-line treatment of Multiple Myeloma
Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.
1 Changing Patient Care in Multiple Myeloma: The IMF Nurse Leadership Board’s Long-Term Survivorship Care Plan Accredited by Medical Education Resources.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria MULTIPLE MYELOMA.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Multiple Myeloma Update from the American Society of Clinical Oncology (ASCO) 43 rd Annual Meeting Welcome and Introduction Nikhil Munshi, MD Dana-Farber.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Sergio Giralt defends the PRO position To Maintain or Not to Maintain The Answer is Yes And Lenalidomide is the Right Choice.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
Disclosures for Palumbo Antonio, MD
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald Marit, M.D., Denis Caillot, M.D., Philippe Moreau, M.D., Thierry Facon, M.D., Anne Marie Stoppa,
Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 88:226–235, R4 신재령.
Lenalidomide plus dexamethasone is more effective than dexamethasone alone inpatients with relapsed or refractory multiple myeloma regardless of prior.
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
Morie Gertz Chair Dept. of Medicine
Palumbo A et al. Proc ASH 2012;Abstract 200.
GEM2005MAS65 Trial: Bortezomib-Based Maintenance Increases CR Rate and PFS in Elderly Patients With Newly Diagnosed Multiple Myeloma Slideset on: Mateos.
Multiple Myeloma in the Non-transplant Setting
Attal M et al. Proc ASH 2010;Abstract 310.
Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Mateos MV et al. Proc ASH 2013;Abstract 403.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Challenging Cases in Multiple Myeloma Panel Discussion
Attal M et al. Proc ASCO 2010;Abstract 8018.
James R. Berenson, MD Medical & Scientific Director
Evangelos Terpos, MD Department of Clinical Therapeutics,
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Vesole DH et al. Proc ASH 2010;Abstract 308.
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 
Maintenance therapies in Multiple Myeloma
Presentation transcript:

Treatment For Newly Diagnosed Myeloma Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Treatment For Newly Diagnosed Myeloma A. Keith Stewart There are many factors which must be considered when developing a treatment plan for a patient with myeloma…first among those is the age of the patient

Risk Adapted Therapy Renal function Co morbid conditions Age Risk Profile Geography Access Patient Preference

mSMART 2.0: Classification of Active MM High-Risk 20% Intermediate-Risk 20% Standard-Risk 60% ** FISH Del 17p t(14;16) t(14;20) GEP High risk signature FISH t(4;14)* Cytogenetic Deletion 13 or hypodiploidy PCLI >3% All others including: Hyperdiploid t(11;14)*** t(6;14) * Prognosis is worse when associated with high beta 2 M and anemia ** LDH >ULN and beta 2 M > 5.5 in standard risk may indicate worse prognosis *** t(11;14) is associated with plasma cell leukemia

Initial Therapy Considerations Ensure patient does not have smoldering (asymptomatic) MM Approach to therapy is based on whether a pt is a transplant candidate Consider clinical trials if available Improving complete response rates is a key goal of current trials

Initial Approach to Treatment Clearly not a transplant candidate Potential transplant candidate Can include melphalan- based combinations Non-alkylator based induction Stem cell harvest

Therapy Options: NonTransplant Candidate Melphalan + Prednisone (MP) Melphalan + Prednisone + Thalidomide (MPT) Melphalan + Prednisone + Bortezomib (MPV) Dexamethasone (Dex) Thalidomide + Dexamethasone (Thal/Dex) Lenalidomide + Dexamethasone (Rev/Dex) NCCN Practice Guideline-v.2.2008

Therapies for younger patients 7

Transplant ? 8

What About Maintenance Thalidomide CR rate PFS (year) OS (year) Barlogie 668 400 mg Taper 62% vs. 43% 5-year 56% vs. 44% 6-year Superior for Thal in CA abnormal Attal 597 Until progression or adverse event 67% vs. 55% 4-year 52% vs. 36% 87% vs. 77% Spencer 243 200 mg 12 months 63% vs. 40% 3-year 63% vs. 36% 90% vs. 81% Barlogie, Tricot, et al, 2006; Attal et al, 2003; Spencer et al, 2009.

IFM 2005-02: Study design Phase III randomized, placebo-controlled trial N= 614 patients, from 78 centers, enrolled between 7/2006 and 8/2008 Patients < 65 years, with non-progressive disease,  6 months after ASCT in first line Randomization: stratified according to Beta-2m, del13, VGPR Consolidation: Lenalidomide alone 25 mg/day p.o. days 1-21 of every 28 days for 2 months We thus designed the IFM 200502 protocol. Patients under the age of 65, with a non progressive disease, within 6 months after a transplant performed as part of their first line therapy were randomized to receive a consolidation treatment with revlimid 25 mg/d , 21 days per month for 2 months followed by maintenance treatment with low dose of revlimid 10-15 mg/ until relapse or placebo Randomization was stratified according to beta 2, del 13, and VGPR Arm A= Placebo (N=307) until relapse Arm B= Lenalidomide (N=307) 10-15 mg/d until relapse Primary end-point: PFS. Secondary end-points: CR rate, TTP, OS, feasibility of long-term lenalidomide…. 10

PFS according to Response Pre-Consolidation VGPR or CR PR or SD p<10-5 p=0.001 HR= 0.37 - CI 95% [0.25-0.58] HR= 0.54 - CI 95% [0.37-0.78]

Lenalidomide Maintenance: TTP Median TTP: Not yet reached Median TTP 25.5 mos Median Follow up from randomization is 12 months CALGB 100104, Nov 2009

MPR-R vs. MPR Progression-Free Survival Median PFS Not reached 13.2 months HR 0.530 100 75 50 25 5 PFS Time (months) 10 15 20 30 Patients without Event (%) At time of data cut-off (April 15, 2009) 50% of patients had continued to maintenance therapy phase Median duration of therapy was 9 cycles Only 8% of patients receiving lenalidomide maintenance required dose reduction suggesting continued treatment is well tolerated Palumbo et al, 2009

How to treat standard risk disease 1. OS is 80% at 5 years (before routine maintenance adopted) 2. No difference in induction regimens (needs further study) 3. A drug regimen which results in high overall response rates and which avoids extremes of toxicity (Rd, weekly bortezomib, MPT) 4. Transplant indicated in younger but may be deferred 5. Maintenance likely helps All others including: Hyperdiploid t(11;14)*** t(6;14) Choice of induction should acknowledge long survival At times transplant can be deferred

How to Treat Standard Risk Disease All others including: Hyperdiploid t(11;14)*** t(6;14) 150 transplant eligible standard risk patients treated with RD, CRD or CBD +/- HDM.

How to treat Intermediate Risk Disease FISH t(4;14) Cytogenetic Deletion 13 or hypodiploidy PCLI >3% Bortezomib-Dex better than VAD Pre transplant

Short remission post transplant despite high response rates All others Del 17 t(4;14) Despite the high responses with CyBorD, high risk cytogenetics by FISH still predicts for early relapse and progression in this population. 4 cycles of CyborD induction and high dose melphalan

Prolonged use of Bortezomib may help overcome intermediate risk FISH t(4;14)* Cytogenetic Deletion 13 or hypodiploidy PCLI >3% VMP standard risk (N=142): not reached (16 events) VMP high risk (N=26): not reached (3 events)

IFM2005: Len maintenance improves PFS even with elevated ß2-m ß2-m  3 mg/l ß2-m > 3 mg/l p<10-5 p=0,0002 Attal et al. 2010

How to treat Intermediate Risk Disease A bortezomib based multi-agent chemotherapy (CyborD, VRD, VTD, MPV) which maximizes CR Longer duration of bortezomib Autologous transplant Consider Consolidation if not in CR IMID based Maintenance Consider targeted therapy approach on trials Intermediate-Risk FISH t(4;14)* Cytogenetic Deletion 13 or hypodiploidy PCLI >3%

High Risk Disease: Not very effective Velcade Dex Tandem Autologous Transplant Allogeneic Transplant Maintenance Thalidomide

POSSIBLY HELPFUL Chemotherapy targeting proliferation ? Longer duration bortezomib ? Lenalidomide maintenance ? New drugs

How to treat High risk disease This population needs novel ideas and therapeutic concepts 2. A multi drug regimen incorporating all available drugs which emphasizes durable CR and uses longer duration of therapy may improve outcomes for p53 deletion 3. Transplant contribution is however of dubious benefit and IMID based maintenance still uncertain High-Risk FISH Del 17p t(14;16) t(14;20) GEP High risk signature

mSMART 2.0: Treatment of Active MM High-Risk Intermediate-Risk Standard-Risk Novel approaches New drugs “TT3 like” approach for p53 deletion ? Prolonged Bortezomib based combination HDM +/- consolidation Lenalidomide maintenance Targeted therapy Regimen which provides a high ORR and which minimizes early toxicity HDM could be delayed in patients achieving CR Lenalidomide maintenance

The Debate Will Continue While risk adapted therapy is appealing, randomized trial data is largely lacking: Minimize toxicity argument: High risk patients do less well even with very aggressive therapy so quality of life more important. Lower risk patients should be treated with focus on lower toxicity as survival long anyway. Maximize therapy argument: Although less aggressive therapy for standard risk disease may result in good outcomes most patients still relapse so all deserve the most intensive therapy